Nectin Therapeutics Ltd. is a biotechnology company, pioneering the development of next generation Immune Oncology (IO) therapies with the potential to set a new standard for efficacy and response rates, across various cancers.

The company’s technology addresses major escape mechanisms of current IO therapy through a diverse pipeline of novel monoclonal antibodies and antibody drug conjugates (ADCs).

Nectin Therapeutics’ lead asset demonstrates excellent preclinical activity and strong scientific rationale to overcome resistance to existing IO drugs.